Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast cancer that has been treated previously with standard surgery, radiotherapy, chemotherapy, or immunotherapy or for which no available treatment options currently exist * Confirmed overexpression of interleukin-4 receptors * Measurable disease (lesions greater than 10 mm by CT scan) OR * Evaluable disease * No prior or concurrent clinically significant brain metastases * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 18 and over Sex: * Male or female Menopausal status: * Not specified Performance status: * Karnofsky 70-100% Life expectancy: * More than 12 weeks Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * Transaminases no greater than 1.5 times ULN * Albumin at least 2.5 g/dL * Hepatitis B surface antigen negative * Hepatitis C antibody negative * No prior or concurrent hepatic disease (e.g., hepatitis or alcoholic liver disease) Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * See Surgery * Electrocardiogram normal * MUGA scan normal * No congestive heart failure * No cardiac arrhythmia requiring treatment * No myocardial infarction * No clinical evidence of coronary artery disease (unless there is a cardiac evaluation and evidence of adequate coronary function by a stress test or angiography) Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 4 weeks before, during, and for at least 3 months after study * No concurrent underlying medical condition that would preclude study or cannot be controlled * No active infection PRIOR CONCURRENT THERAPY: Biologic therapy: * See Disease Characteristics Chemotherapy: * See Disease Characteristics * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy Surgery: * See Disease Characteristics * At least 1 year since prior surgery or angioplasty for coronary artery disease Other: * At least 28 days since prior experimental drugs and recovered